MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/4/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH

6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Get Alerts MGTX Hot Sheet

Price: $13.89 -0.57%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor and scientific conferences:

Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Corporate Presentation: Monday, April 25, 2022, at 10:30 a.m. ET

Panel Discussion: – “Evolving standards of AAV GT manufacturing – learnings from experience in registration-targeted trials”, Monday, April 25, 2022, at 12:00 p.m. ET

Mass General Brigham World Medical Innovation Forum

Panel Discussion: – “Gene and Cell Therapy Safety – Enduring Framework Required”, Wednesday, May 4, 2022, at 9:55 a.m. ET

BofA Securities 2022 Healthcare Conference

Corporate Presentation: Tuesday, May 10, 2022, at 1:00 p.m. ET

2022 RBC Capital Markets Global Healthcare Conference

Corporate Presentation: Wednesday, May 18, 2022, at 3:35 p.m. ET

A live webcast of the corporate presentations will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology which allows tight, dose responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:MeiraGTx[email protected]

Media:Jason Braco, Ph.D.LifeSci Communications[email protected]